Celldex Therapeutics (CLDX) Current Assets (2010 - 2026)

Celldex Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $459.2 million for Q1 2026.

• In Q1 2026, Current Assets fell 33.81% year-over-year to $459.2 million; the TTM figure through Mar 2026 stood at $459.2 million (down 33.81% YoY), while the FY2025 annual figure was $534.7 million, down 28.44% from the prior year.
• Current Assets for Q1 2026 stood at $459.2 million, down from $534.7 million in the prior quarter.
• The five-year high for Current Assets was $835.3 million in Q1 2024, with the low at $245.9 million in Q3 2023.
• The 5-year median for Current Assets is $459.2 million (2026), against an average of $515.1 million.
• The sharpest annual moves came in 2024 and 2026: Current Assets soared 216.69% in 2024, then slumped 33.81% in 2026.
• Celldex Therapeutics' Current Assets stood at $317.7 million in 2022, then soared by 35.88% to $431.7 million in 2023, then surged by 73.08% to $747.2 million in 2024, then slipped by 28.44% to $534.7 million in 2025, then fell by 14.11% to $459.2 million in 2026.
• Business Quant data shows CLDX's Current Assets at $459.2 million in Q1 2026, $534.7 million in Q4 2025, and $604.3 million in Q3 2025.